Published in
Elsevier, European Journal of Cancer, (106), p. 234-243, 2019
DOI: 10.1016/j.ejca.2018.11.007
Links
Tools
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
Journal article published in 2019 by
Markus Eckstein 
,
Philipp Erben ,
Maximilian C. Kriegmair,
Thomas S. Worst,
Cleo-Aron Weiß,
Ralph M. Wirtz,
Sven Wach,
Robert Stoehr,
Danijel Sikic,
Carol I. Geppert,
Veronika Weyerer,
Simone Bertz,
Johannes Breyer,
Wolfgang Otto,
Bastian Keck
and other authors.
,
Philipp Erben ,
Maximilian C. Kriegmair,
Thomas S. Worst,
Cleo-Aron Weiß,
Ralph M. Wirtz,
Sven Wach,
Robert Stoehr,
Danijel Sikic,
Carol I. Geppert,
Veronika Weyerer,
Simone Bertz,
Johannes Breyer,
Wolfgang Otto,
Bastian Keck
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 